Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies For the purpose of this review, we use trastuzumab-induced ...
* Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 ...
Herceptin with chemotherapy improved OS and PFS in HER2-positive gastric cancers, but benefits decreased after chemotherapy regimen changes. Major pathological response rates were higher with ...
Trastuzumab and T-DXd are effective in HER2-positive gastric and GEJ cancers, moving towards earlier intervention stages. A meta-analysis of T-DXd showed significant efficacy and manageable safety in ...
A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer. This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results